The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Bisaga G.N.

Voenno-meditsinskaia akademiia im. S.M. Kirova, klinika nervnykh bolezneĭ, Sankt-Peterburg;
Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Briukhov V.V.

Briukhov V.V.

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Zakharova E.V.

Department of Nephrology, S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Department of Nephrology, Faculty of Advanced Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Salogub G.N.

St. Petersburg

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Salogub G.N.

St. Petersburg

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Clinical recommendations on the use of alemtuzumab (lemtrada)

Authors:

Alifirova V.M., Bisaga G.N., Boĭko A.N., Briukhov V.V., Briukhov V.V., Davydovskaya M.V., Zakharova M.N., Zakharova E.V., Malkova N.A., Popova E.V., Salogub G.N., Sivertseva S.A., Salogub G.N., Troshina E.A., Khachanova N.V., Shmidt T.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2‑2): 115‑126

DOI: 10.17116/jnevro201711722115-126

Read: 6088 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL RECOMMENDATIONS ON THE USE OF ALEMTUZUMAB (LEMTRADA)
CLINICAL RECOMMENDATIONS ON THE USE OF ALEMTUZUMAB (LEMTRADA)

To cite this article:

Alifirova VM, Bisaga GN, Boĭko AN, et al. Clinical recommendations on the use of alemtuzumab (lemtrada). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2‑2):115‑126. (In Russ.)
https://doi.org/10.17116/jnevro201711722115-126

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Resu­lts of 4 years of therapy with divo­zilimab in patients with rela­psing multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

Keywords:

alemtuzumab
alemtuzumab
alemtuzumab
alemtuzumab
multiple sclerosis
multiple sclerosis
multiple sclerosis
multiple sclerosis
monoclonal antibody
monoclonal antibody
monoclonal antibody
monoclonal antibody

Authors:

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Bisaga G.N.

Voenno-meditsinskaia akademiia im. S.M. Kirova, klinika nervnykh bolezneĭ, Sankt-Peterburg;
Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Briukhov V.V.

Briukhov V.V.

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Zakharova E.V.

Department of Nephrology, S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Department of Nephrology, Faculty of Advanced Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Salogub G.N.

St. Petersburg

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Salogub G.N.

St. Petersburg

Troshina E.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Close metadata

References:

  1. Freedman MRush C. Severe, Highly Active, or Aggressive Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology. 2016;22:761-784. doi:10.1212/con.0000000000000331
  2. Sorensen P. New management algorithms in multiple sclerosis. Current Opinion in Neurology. 2014;27(3):246-259. doi:10.1097/wco.0000000000000096
  3. Freedman M. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon- β therapy. European Journal of Neurology. 2013;21(3):377-320. doi:10.1111/ene.12299
  4. Instructions for use of the drug Lemtrada. 2016. (In Russ.).
  5. Freedman M. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. Journal of Clinical & Cellular Immunology. 2013;04(04). doi:10.4172/2155-9899.1000152
  6. Hassoun L, Eisele J, Thomas K, Ziemssen T. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders. 2016;1(1). doi:10.1186/s40893-016-0011-1
  7. Khasaeva M, Gorokhova T, Boyko A, Gusev E. Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review) Journal of neurology and psychiatry im. S.S. Korsakova. 2013;113:87-92. (In Russ.).
  8. Coles A. Alemtuzumab Therapy for Multiple Sclerosis. Neurotherapeutics. 2012;10(1):29-33. doi:10.1007/s13311-012-0159-0
  9. Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. New England Journal of Medicine. 2008;359(17):1786-1801. doi:10.1056/nejmoa0802670
  10. Bourdette D Yadav V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Current Neurology and Neuroscience Reports. 2009;9(5):341-342. doi:10.1007/s11910-009-0062-1
  11. Coles A, Twyman C, Arnold D et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012;380(9856):1829-1839. doi:10.1016/s0140-6736(12)61768-1
  12. Montalban X, Inshasi J, Coles A et al. Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study. Multiple Sclerosis and Related Disorders. 2014;3(6):761-762. doi:10.1016/j.msard.2014.09.207
  13. Coles A, Fox E, Vladic A et al. Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 2012;78(14):1069-1078. doi:10.1212/wnl.0b013e31824e8ee7
  14. Kieseier B, Sahraian M, Coles A et al. Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study. Multiple Sclerosis and Related Disorders. 2014;3(6):756. doi:10.1016/j.msard.2014.09.194
  15. Perumal J Khan O. Emerging Disease-Modifying Therapies in Multiple Sclerosis. Current Treatment Options in Neurology. 2012;14(3):256-263. doi:10.1007/s11940-012-0173-x
  16. Coles A, Cox A, Page E et al. The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology. 2005;253(1):98-108. doi:10.1007/s00415-005-0934-5
  17. Willis MRobertson N. Alemtuzumab for the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management. 2015:525. doi:10.2147/tcrm.s80112
  18. Nicholas RJ, Morgan-Followell B, Pitt D, Boster RA. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal of Central Nervous System Disease. 2012:81. doi:10.4137/jcnsd.s6692
  19. Davidovskay MV, Hachanova NV, Evdoshenko EP Pronin IN, Boyko AN, Zakharova MN, Alifirova VM, Turova EA, Malkova NA, Sivertseva SA, Cukurova L.A Skoromets AA, Solodun IYu. Recommendations for the selection algorithm of the drug and the risk management plan natalizumab therapy in patients with relapsing-remitting multiple sclerosis. Journal of neurology and psychiatry S.S. Korsakov. 2016;116:10(2). (In Russ.). doi:10.17116/jnevro2016116102?-?
  20. Criteria of treatment failure and the cancellation of DMD of the first line and replace to second-line drugs. Journal of neurology and psychiatry S.S. Korsakov. 2015;115:8(2):44. (In Russ.). doi:10.17116/nevro20151158244
  21. Cossburn M, Pace A, Jones J et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579. doi:10.1212/wnl.0b013e318228bec5
  22. Takata K. Congress report of the sixth triennial joint Americas Committee for Treatment and Research in Multiple Sclerosis-European Committee for Treatment and Research in Multiple Sclerosis meeting in Boston. Clinical and Experimental Neuroimmunology. 2015;6(1):103-106. doi:10.1111/cen3.12176
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.